EYENOVIA INC (EYEN)
US30234E1047 - Common Stock
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering
NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and...
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering
NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and...
Eyenovia Provides Update on Restructuring Efforts
Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues...
Eyenovia Provides Update on Phase 3 CHAPERONE Study
A review of study data by an independent Data Review Committee found that CHAPERONE is not meeting its primary three-year efficacy endpoint Company to...
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter Commenced...
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
Company to host an investor conference call and webcast at 4:30pm EDT...
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®
Publication in the Journal of Ocular Pharmacology and Therapeutics highlights the ability of the Optejet to achieve a therapeutic dose of medication with...
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
Presentation details efficacy and tolerability results from the successful Phase 3 program that led to FDA approval of clobetasol propionate suspension...
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
The Gen-2 Optejet is designed for an optimized user experience while ensuring extended patent protection for products using the platform through 2041...
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company with two...
Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
New market research shows strong interest from ophthalmic surgeons following their review of Clobetasol’s prescribing information...
Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization
/PRNewswire/ -- Formosa Pharmaceuticals, Inc. (hereinafter referred to as "Formosa Pharma," 6838.TW) announced the successful first shipment to the United...
Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.
Eyenovia is planning for a U.S. launch for Clobetasol in late September 2024...
Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer
Current CFO, John Gandolfo, to remain with the Company through November as part of planned retirement transition...
Eyenovia Announces Closing of Public Offering
NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced...
Eyenovia Announces Pricing of $5.14 Million Public Offering
NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced...
Eyenovia, Inc. Announces Proposed Public Offering
NEW YORK, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, announced...
EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q2 2024
EYEN stock results show that Eyenovia missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Eyenovia (NASDAQ:EYEN) just reported results for the second quarter of 2024.Eye...
Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Following FDA consultation, announced plans for validation of the Gen-2 Optejet® device and 2025 regulatory submission with Mydcombi™ as lead product ...
Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th
Company to host an investor conference call and webcast at 4:30pm EDT...
Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S.
Product-candidate would incorporate new steroid with the Optejet® for the millions of dry eye patients who experience periodic flare-ups...